Oxford and GSK launch £50m programme to advance cancer research
Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.
Read moreLatest News
Anchoring a key immune molecule boosts T cell responses
11 March 2026
Paresh Vyas receives CRUK Discovery Programme Award
11 March 2026
Upcoming Talks
The Oxford Cancer Annual Symposium supported by the CRUK Oxford Centre 2026
Tuesday, 31 March 2026, 8.30am to 6.30pm
Organelle Pharmacology – a new frontier for drug discovery (15-16 April 2026)
Wednesday, 15 April 2026 to Thursday, 16 April 2026, 9am - 4pm
Latest publications
DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models.
Journal article
Morgado-Cáceres P. et al, (2026), Oncoimmunology, 15
Systematic review and data-driven insights into CHO cell engineering for next-generation antibody production.
Journal article
Schulz A. et al, (2026), MAbs, 18
Ginkgo Datapoints Antibody Developability Competition outcomes: limited model performance and a call for data standardization.
Journal article
van Niekerk L. et al, (2026), MAbs, 18
Spatio-temporal eco-evolutionary dynamics of prey-predator systems with defended and undefended prey
Preprint
Roy S. et al, (2026)